Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.
Description for laymen
The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.
JSON Data
{
"short_title": "ABC-HCC",
"data_mode": "900",
"data_mode_number": "000002319",
"official_title": "The ABC-HCC Trial: A Phase IIIb, Randomized, Multicenter, Open-label Trial of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": "NCT04803994",
"eudract_number": null,
"general_contact_email": "oncostudy@ukdd.de",
"general_contact_phone": "+49 351-4587666",
"hauptpruefer_dd_name": "Dr. med. Anke Kr\u00f6cher",
"description_laie_de": "Die ABC-HCC-Studie ist eine randomisierte, multizentrische, offene Phase-IIIb-Studie zur Untersuchung der Sicherheit und Wirksamkeit von Atezolizumab plus Bevacizumab im Vergleich zu TACE bei Patienten mit HCC im mittleren Stadium. Es werden etwa 434 Patienten in zwei Behandlungsarme aufgenommen.",
"description_laie_en": "The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.",
"description_expert_de": "Eine randomisierte, multizentrische, unverblindete klinische Studie der Phase IIIb zur Pr\u00fcfung der Kombination von Atezolizumab plus Bevacizumab gegen \r\ntransarterielle Chemoembolisation (TACE) bei Patienten mit intermedi\u00e4ren Hepatozellul\u00e4rem Karzinom. Es werden etwa 434 Patienten in zwei Behandlungsarme aufgenommen.",
"description_expert_en": "The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "III",
"main_cat_id": 2,
"sub_cat_id": 7
}
